Have any questions? 706-721-6582 or cts@augusta.edu
- REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP): COVID-19 (REMAP-COVID) / RCC2116
Clinical Trial
REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP): COVID-19 (REMAP-COVID) / RCC2116
The goal of the Core Protocol (main or parent study) is to identfy the effect of different treatments to improve the outcome for patients with suspected or provden COVID-19 infection. The specific sub-protocol being conducted here, called a Domain, has the primary goal to see how effective different immune modulating medications are in decreasing inflammation response to the infection, which may help decrease damage to organs that can lead to complications.
- Coronavirus Disease (COVID
- COVID-19
- Immune Modulation
- Inflammation
- Inflammatory Response
- REMAP
- SARS-CoV-2)
Eligibility Criteria
- INCLUSION: 1. Confirmed SARS-CoV-2 infection in adults age 18 or older. EXCLUSION: 1. Patient is or has taken medications that are not allowed by the study 2. Current health conditions or lab values not allowed by the study
RESEARCH. INNOVATION. DISCOVERY.